Gene Testing To Tailor Breast Cancer Therapy Has Arrived—Is It Ready for the Clinic?

Sinha, Gunjan
August 2008
JNCI: Journal of the National Cancer Institute;8/6/2008, Vol. 100 Issue 15, p1050
Academic Journal
The article offers information on the use of gene testing for breast cancer therapy. It is mentioned that the cytochrome P450 2D6 (CYPD6) gene may not respond to tamoxifen, a drug used to treat breast cancer. Oncologists are split on the issue whether this gene test is an effective form in interpreting estrogen receptor-positive breast cancer. Some believe that the method is too premature.


Related Articles

  • Fulvestrant: A Viewpoint by Roger W. Blamey. Blamey, R.W. // Drugs;Apr2001, Vol. 61 Issue 6, p814 

    Presents information on fulvestrant, an anti-estrogen antagonist, indicated for treating breast cancer. Comparison between fulvestrant and tamoxifen as estrogen receptors; Limitations of the effect of the fulvestrant.

  • Tamoxifen: In whose best interest? Oakley, Ann // New Scientist;6/22/91, Vol. 130 Issue 1774, p12 

    Discusses the issues involved in the trials of tamoxifen for the treatment of breast cancer. Study by Trevor Powles of the Royal Marsden Hospital in England; Statistics of breast cancer in the UK; Need for women in the study to be given clear and complete information about the drug; History of...

  • Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Mojarrad, Majid; Momeny, Majid; Mansuri, Fatemeh; Abdolazimi, Yassan; Tabrizi, Mina Hajifaraj; Ghaffari, Seyed Hamidollah; Tavangar, Seyed Mohammad; Modarressi, Mohammad Hussein // Medical Oncology;Jun2010, Vol. 27 Issue 2, p474 

    Tamoxifen is the most common antiestrogen used in the treatment of estrogen-positive breast cancer but its adverse effects and also resistance to this drug are serious challenges in the treatment of breast cancer. Characterization of mechanisms responsible for these adverse effects can lead to...

  • Delivering tamoxifen within solid lipid nanoparticles. Abbasalipourkabir, Roghayeh; Salehzadeh, Aref; Abdullah, Rasedee // Pharmaceutical Technology Europe;Apr2011, Vol. 23 Issue 4, p22 

    Solid lipid nanoparticles (SLNs) have been proposed as an alternative colloidal drug-delivery system for water-soluble drugs. The aim of this study was to prepare and characterise physiochemically and biologically tamoxifen-loaded SLNs to evaluate their effectiveness as a drug-delivery system to...

  • Tamoxifen Resistance in Breast Cancer: Elucidating Mechanisms. Dorssers, L.C.J.; van der Flier, S.; Brinkman, A.; van Agthoven, T.; Veldscholte, J.; Berns, E.M.J.J.; Klijn, J.G.M.; Beex, L.V.A.M.; Foekens, J.A. // Drugs;Sep2001, Vol. 61 Issue 12, p1721 

    Tamoxifen has been used for the systemic treatment of patients with breast cancer for nearly three decades. Treatment success is primarily dependent on the presence of the estrogen receptor (ER) in the breast carcinoma. While about half of patients with advanced ER-positive disease immediately...

  • Breast cancer: Tamoxifen benefits node-positive elders after mastectomy.  // Geriatrics;Aug1991, Vol. 46 Issue 8, p17 

    This article presents a study, conducted by Frank Cummings and colleagues, who analyzed findings in 168 older women with node-positive breast cancer who were treated for 2 years following mastectomy with either tamoxifen, 20 mg/d, or placebo. Of 102 deaths in this series, 61% were due to breast...

  • Tamoxifen Update. Sugerman, Deborah Tolmach // JAMA: Journal of the American Medical Association;8/28/2013, Vol. 310 Issue 8, p866 

    The article provides information on the drug Tamoxifen. Tamoxifen is a drug that blocks the effects of the hormone estrogen. It is used as a treatment for breast cancer patients whose tumors have estrogen receptors, called ER positive. It is often used after surgery or radiation therapy and also...

  • δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer. Shaocong Guo; Yaqing Li; Qi Tong; Feng Gu; Tianhui Zhu; Li Fu; Shuang Yang // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Resistance to tamoxifen therapy represents a major barrier to the successful treatment of breast cancer, where a loss of or reduced ER-α level is considered a primary mechanism. Understanding how ER-α expression is regulated would provide insights into new intervention points to overcome...

  • anti-oestrogen drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p58 

    An encyclopedia entry for an "anti-oestrogen drugs" is presented. They refer to a group of drugs that contrast the action of the hormone oestrogen. Tamoxifen, which is used in the treatment of certain breast cancers, is said to be the most important of these drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics